Brief: Bergenbio Q1 Operating Loss Widens To NOK 56.2 Mln

Oncoinvent ASA

19/05/2020 06:03

May 19 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * : RESULTS FOR THE FIRST QUARTER 2020
    * Q1 OPERATING REVENUE NOK 0 MILLION VERSUS NOK 8.7 MILLION
YEAR
AGO
    * Q1 TOTAL OPERATING EXPENSES WERE NOK 56.2 MILLION (NOK
54.5
MILLION)
    * Q1 OPERATING LOSS FOR QUARTER CAME TO NOK 56.2 MILLION
(NOK 45.8
MILLION)
    * IMPACT OF COVID-19 ON OUR CLINICAL TRIALS STARTED TO
BECOME
VISIBLE TOWARDS END OF Q1 AND ON OUR PRECLINICAL RESEARCH
OPERATIONS IN APRIL

Source text for Eikon:  ID:nWkr84rtNT 
Further company coverage:  BGBIO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))